Perhaps the short follow‐up time (median 2.1 years) and high frequency of positive surgical margins in TCGA‐PRAD prohibited validation of HLA‐A*02:01 as a biomarker of prostate cancer progression. This evidence concerns the gene HLA-A and prostate cancer.